同步度伐利尤单抗联合铂类放化疗治疗不可切除III期NSCLC:III期PACIFIC-2研究
PACIFIC-2研究纳入328例不可切除III期NSCLC患者,随机2:1接受度伐利尤单抗或安慰剂从同步放化疗开始给药。结论提示从cCRT开始给予度伐利尤单抗未显示额外获益,cCRT后度伐利尤单抗巩固治疗仍是标准治疗。
要点
- 度伐利尤单抗组和安慰剂组确认ORR分别为60.7%和60.6%,差异无统计学意义。
- cCRT后度伐利尤单抗巩固治疗仍是不可切除III期NSCLC的标准治疗。
核心结论
- 在不可切除III期NSCLC中,从cCRT开始给予度伐利尤单抗较安慰剂未显著改善PFS或OS。
- cCRT后度伐利尤单抗巩固治疗仍是该人群的标准治疗。
研究设计与样本
- III期PACIFIC-2研究, eligible患者随机2:1接受度伐利尤单抗(n=219)或安慰剂(n=109),从cCRT开始给药,完成后无进展者继续巩固治疗至进展。
- 主要终点为盲法独立中心审查的PFS,关键次要终点包括ORR、OS、24个月生存比例(OS24)和安全性。
主要发现
- 度伐利尤单抗组与安慰剂组最大3或4级AE发生率分别为53.4%和59.3%,肺炎或放射性肺炎(组术语)分别为28.8%(≥3级4.6%)和28.7%(≥3级5.6%)。
- 导致度伐利尤单抗或安慰剂停药的AE分别为25.6%和12.0%,致死性AE分别为13.7%和10.2%。
临床怎么用
- 不可切除III期NSCLC患者不应在cCRT同时开始度伐利尤单抗治疗。
- 应继续采用cCRT后度伐利尤单抗巩固治疗作为标准方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Immunotherapy targeting PD-L1 improves outcomes in patients with unresectable stage III non-small cell lung cancer (NSCLC) and no progression after definitive, concurrent chemoradiotherapy (cCRT). Earlier administration of immunotherapy, simultaneously with cCRT, may improve outcomes further. METHODS: Eligible patients were randomly assigned (2:1) to receive either durvalumab or placebo administered from the start of cCRT. Patients without progression after completing cCRT received consolidation durvalumab or placebo (per initial random assignment) until progression. The primary end point was progression-free survival (PFS) by blinded independent central review. Key secondary end points included objective response rate (ORR), overall survival (OS), the proportion of patients alive at 24 months (OS24), and safety. RESULTS: In total, 328 patients were randomly assigned to receive durvalumab (n = 219) or placebo (n = 109). There was no statistically significant difference with durvalumab versus placebo in PFS (hazard ratio [HR], 0.85 [95% CI, 0.65 to 1.12]; P = .247) or OS (HR, 1.03 [95% CI, 0.78 to 1.39]; P = .823); OS24 was 58.4% versus 59.5%, respectively. Confirmed ORR was 60.7% with durvalumab versus 60.6% with placebo (difference, 0.2% [95% CI, -15.2 to 16.3%]; P = .976). With durvalumab versus placebo, respectively, maximum grade 3 or 4 adverse events (AEs) occurred in 53.4% versus 59.3% of patients, pneumonitis or radiation pneumonitis (group term) in 28.8% (grade ≥3: 4.6%) versus 28.7% (grade ≥3: 5.6%), AEs leading to discontinuation of durvalumab or placebo in 25.6% versus 12.0%, and fatal AEs in 13.7% versus 10.2%. CONCLUSION: Among patients with unresectable stage III NSCLC, durvalumab administered from the start of cCRT failed to demonstrate additional benefit compared with cCRT plus placebo. Consolidation durvalumab following definitive cCRT remains the standard of care in this setting.
引用
- Bradley JD, Sugawara S, Lee KH, et al. Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study. J Clin Oncol. 2025. PMID: 41082707. doi:10.1200/JCO-25-00036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。